
## Supplementary Information

## The nuclear receptor NOR-1 regulates the small muscle protein, X-linked (SMPX) and myotube differentiation


Beatriz Ferrán<sup>1</sup>, Ingrid Martí-Pàmies<sup>1</sup>, Judith Alonso<sup>1</sup>, Ricardo Rodríguez-Calvo<sup>1</sup>, Silvia Aguiló<sup>1</sup>, Francisco Vidal<sup>2</sup>, Cristina Rodríguez<sup>1</sup>\* & José Martínez-González<sup>1</sup>\*

<sup>1</sup>Centro de Investigación Cardiovascular, CSIC-ICCC, IIB-Sant Pau, c/Sant Antoni Maria Claret 167, 08025 Barcelona, Spain. <sup>2</sup>Unitat de Diagnòstic i Teràpia Molecular, Banc de Sang i Teixits, Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain.


\* The last two authors contributed equally to this work




**Supplementary Fig. S1. Lentiviral over-expression of NOR-1 in human VSMC.** (a) Human VSMC were transduced with pLVX or pLVX/NOR-1-FLAG (pNOR-1F) lentivirus, and NOR-1 over-expression was verified by real-time PCR (n = 6). \*P < 0.0001 *vs.* cells transduced with pLVX. (b) Immunocytochemical analysis for NOR-1 using an antibody against the FLAG sequence (FLAG), from cells transduced as indicated in (a). Bottom panels: fluorescent labelling of nuclei using Hoechst. Bars: 25 µm.




Supplemetary Fig. S2. Lentiviral NOR-1 over-expression reduces VSMC proliferative rate and promotes VSMC hypertrophy. (a) VSMC were transduced with a lentiviral vector to over-express NOR-1 (pLVX/NOR-1; pNOR-1), or a control lentiviral vector expressing EGFP (pLVX/EGFP; pGFP), and the proliferative rate of VSMC cultures was determined by daily cell counting. Non-infected cells (NI) were used as a control. (b and c) Relative cellular protein content (total protein content/ cell number) (b) and relative cell surface area (c) of VSMC treated as indicated in (a). \*, \*\*, \*\*\*, P < 0.0001, P = 0.002, P = 0.0077, respectively vs. NI. #, ###, P < 0.0001, P = 0.0003, P = 0.0006, respectively vs. pGFP.




Supplementary Fig. S3. SMPX is expressed in human arteries. (a) SMPX mRNA levels determined by real-time PCR in human skeletal muscle (S. muscle; n = 4), and human vessels: coronary arteries (C. artery; n = 7) and aorta (n = 6). Data are expressed as mean  $\pm$  s.e.m. \*P = 0.0001 and #P = 0.0003 *vs*. S. muscle. (b) Representative Western blot showing SMPX protein levels in these tissues. Levels of  $\beta$ -actin were used as a loading control in Western blot experiments.



Supplementary Fig. S4. SMPX does not seem to be regulated by NOR-1 in mouse. (a) Alignment of the proximal region corresponding to the SMPX promoter from different species including human and mouse. Non-conserved positions are indicated in lower case. The NBRE consensus sequence (NBRE c.s.) is shown at the top. (b and c) SMPX was not regulated by NOR-1 transgenesis in mice. SMPX mRNA levels were analyzed by real-time PCR in mouse aorta from wild-type (WT; n = 7) and transgenic mice that specifically over-express human NOR-1 in VSMC (TgNOR-1; n = 9) (b), and in cultures of VSMC from these animals (n = 6) (c). Data are expressed as mean  $\pm$  s.e.m.



**Supplementary Fig. S5. SMPX is highly expressed in HSMM.** mRNA levels of SMPX (analysed by real-time PCR) in human VSMC, and in HSMM non-differentiated (ND) and differentiated (D) to myotubes (after the exposition to 2% horse serum during five days) (n = 6). \*P < 0.0001 *vs.* VSMC; \*P < 0.0001 *vs.* ND.



**Supplementary Fig. S6. SMPX expression in mouse tissues.** Expression levels of SMPX analysed by real-time PCR in a set of mouse tissues. WAT: white adipose tissue; S. intestine: small intestine; S. muscle: skeletal muscle. Data are expressed as mean  $\pm$  s.e.m. (n = 7). \*P < 0.0001 *vs.* aorta.